Bone-Targeting Endogenous Secretory Receptor for Advanced Glycation End Products Rescues Rheumatoid Arthritis
- 5 Downloads
Rheumatoid arthritis (RA) is a chronic inflammatory synovitis that leads to the destruction of bone and cartilage. The receptor for advanced glycation end products (RAGE) is a multiligand membrane-bound receptor for high-mobility group box-1 (HMGB1) associated with development of RA by inducing production of proinflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1 and IL-6. We developed a bone-targeting therapeutic agent by tagging acidic oligopeptide to a nonmem-brane-bound form of RAGE (endogenous secretory RAGE [esRAGE]) functioning as a decoy receptor. We assessed its tissue distribution and therapeutic effectiveness in a murine model of collagen-induced arthritis (CIA). Acidic oligopeptide-tagged esRAGE (D6-esRAGE) was localized to mineralized region in bone, resulting in the prolonged retention of more than 1 wk. Weekly administration of D6-esRAGE with a dose of 1 mg/kg to RA model mice significantly ameliorated inflammatory arthritis, synovial hyperplasia, cartilage destruction and bone destruction, while untagged esRAGE showed little effectiveness. Moreover, D6-esRAGE reduced plasma levels of proinflammatory cytokines including TNF-α, IL-1 and IL-6, while esRAGE reduced the levels of IL-1 and IL-6 to a lesser extent, suggesting that production of IL-1 and IL-6 reduced along the blockade of HMGB1 receptor downstream signals by D6-esRAGE could be attributed to remission of CIA. These findings indicate that D6-esRAGE enhances drug delivery to bone, leading to rescue of clinical and pathological lesions in murine CIA.
Rheumatoid arthritis (RA) is a chronic inflammatory synovitis dominated by the presence of macrophages, lymphocytes and synovial fibroblasts, leading to the destruction of bone and cartilage (1). Uncontrolled active RA causes disability, decreases quality of life and increases morbidity. The introduction of novel biologics has revolutionized RA treatment. Their success has underlined the key roles of proinflammatory cytokines in the pathogenesis of inflammatory arthritis, such as tumor necrosis factor (TNF)-α and interleukin (IL)-1 and IL-6 (2, 3, 4). Theoretically, this approach not only enhances the specificity in their effects but diminishes adverse events. Clinical studies on RA patients showed therapeutic efficacy by administering the agents blocking TNF-α, IL-1 and IL-6, namely etanercept (5), anakinra (6) and tocilizumab (7), respectively. However, some patients did not respond to even such advanced biologic agents. Because the pathogenesis of RA is caused by multiple complex factors involving a wide range of molecules, the factors other than TNF-α, IL-1 and IL-6 also participate in the proinflammatory cytokine cascade.
Recent studies revealed that extracellular high-mobility group box 1 (HMGB1) levels in both serum and synovial fluid are significantly elevated in patients with RA (8,9). HMGB1 can bind to the cell surface receptors including toll-like receptor (TLR)-2, TLR-4 and the receptor for advanced glycation end products (RAGE) (10,11). HMGB1 interaction with these receptors transduces intracellular signals and mediates the release of proinflammatory cytokines such as TNF-α in macrophages (9). Moreover, HMGB1 directly induces synovial cell proliferation and osteoclastogenesis, leading to the destruction of cartilage and bone (12, 13, 14). Thus, HMGB1 plays a critical role in the pathogenesis of RA and may become a putative target for successful RA treatment.
RAGE is composed of (a) an N-terminal extracellular domain with a ligandengaging V-region-like domain essential for binding with HMGB1 and two C-region-like domains; (b) a single pass transmembrane domain; and (c) a C-terminal highly charged, short cytoplasmic domain essential for signal transduction (15, 16, 17). A soluble RAGE (sRAGE), a truncated form of the receptor, is composed of only the extracellular ligand-binding domain lacking the cytosolic and transmembrane domains. In humans, sRAGE is produced by alternative splicing of RAGE mRNA (18,19). Yonekura et al. (20) identified a naturally occurring sRAGE lacking transmembrane and intracellular domains in humans and named it endogenous secretory RAGE (esRAGE). This soluble form of the receptor is a C-terminally truncated type and has a V-domain essential for binding with the ligand such as HMGB1. Therefore, esRAGE has the same ligand binding specificity, competes with cell-bound RAGE for ligand binding and functions as a decoy abrogating cellular activation (20,21).
An innovative drug delivery system by using acidic oligopeptides to target bone was proposed and investigated experimentally and clinically (22, 23, 24). This unique approach is based on the physical properties of several noncollagenous bone proteins that have repetitive sequences of acidic amino acids (l-aspartic acid [l-Asp] or l-glutamine [l-Glu]) and bind to hydroxyapatite (HA) (25,26). It was indicated that the antibiotics fluoroquinolones, tagged with an acidic oligopeptide, were successfully targeted to bone and could be effective in treating osteomyelitis if the appropriate dose was given (24). We and other groups have applied this bone-targeting system to large molecules, namely, enzymes (tissue-nonspecific alkaline phosphatase, β-glucuronidase and N-acetylgalactosamine-6-sulfate sulfatase), showing that the tagged enzymes were delivered more efficiently to bone and that the clinical and pathological improvement in bone was observed in murine models of hypophosphatasia, mucopolysaccharidosis VII and mucopolysaccharidosis IVA, respectively (27, 28, 29, 30). The clinical trial for the patients with hypophosphatasia is now in progress with a favorable clinical consequence rescuing the devastating skeletal bone disease (31).
In this study, we applied and developed the bone-targeting drug delivery system for RA by tagging the acidic oligopeptide to esRAGE and evaluated the in vivo therapeutic effect of targeted esRAGE on the RA murine model.
Materials and Methods
Mice and Reagents
Six-week-old male DBA/1J mice were purchased from Japan SLC (Hamamatsu, Japan). All mouse experiments were performed in accordance with the guidelines of the Committee on Animal Experiments at Hokuriku University.
Human lung total RNA was obtained from Clontech (Mountain View, CA, USA). Mammalian expression vector pcDNA3.1 (+), Lipofectamine 2000 and Alexa Fluor 488 Protein Labeling Kit were purchased from Invitrogen/Life Technologies (Carlsbad, CA, USA). Dulbecco’s modified Eagle medium (DMEM) was from Nissui Pharmaceutical (Tokyo, Japan), and EX-CELL® 325 PF CHO Serum-Free Medium for CHO Cells (protein free) was obtained from SAFC Biosciences (Lenexa, KS, USA). G418, DEAE-Sepharose, Sephacryl S-300-HR and Nickel Affinity Gel were purchased from Sigma-Aldrich (St. Louis, MO, USA). Vivacell 70 and Vivaspin 15 centrifugal filter device were from Sartorius Stedim Biotech (Goettingen, Germany).
Coomassie brilliant blue R-250, imidazole, complete Freund adjuvant (CFA) and incomplete Freund adjuvant (IFA) were obtained from Wako (Osaka, Japan). Heparin Sepharose and ECL Plus kit were purchased from GE Healthcare (Chalfont St Giles, Buckinghamshire, UK). Detoxi-gel endotoxin removal gel was from Pierce (Rockford, IL, USA). Peptide N-glycosidase F (PNGase F) was obtained from New England Biolabs (Beverly, MA, USA). Primary anti-RAGE antibody was obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and secondary horseradish peroxidase-conjugated anti-rabbit IgG antibody was purchased from Cell Signaling (Beverly, MA, USA). HA beads were from Bio-Rad Laboratories (Richmond, CA, USA). Recombinant human HMGB1 was obtained from R&D Systems (Minneapolis, MN, USA), and His-tagged recombinant human HMGB1 was purchased from ATGen (Gyeonggi-do, Korea). Mouse monocyte/macrophage cell line RAW264.7 was from American Type Culture Collection (Manassas, VA, USA). Bovine collagen type II was obtained from Cosmo Bio (Tokyo, Japan). TNF-α enzyme-linked immunosorbent assay (ELISA) kit, IL-1 ELISA kit and IL-6 ELISA kit were purchased from R&D Systems.
Production of Untagged and Acidic Oligopeptide-Tagged Human Recombinant esRAGE (GenBank Accession No. AB061668)
To produce acidic oligopeptide-tagged esRAGE, a stretch of 6, 10 or 14 of l-Asp codons (6 l-Asp, 5′-GACGATGACG ACGATGAT-3′: 10 l-Asp, 5′-GACGA TGACGACGATGATGACGACGACGAC-3′: 14 l-Asp, 5′-GACGATGACGACGATGAT GACGACGACGACGATGATGATG AT-3′) was introduced additionally at the C-terminus after c.1041G of Met347 between the spacer (5′-ACCGGTGAAG CAGAGGCC-3′) and a termination codon. The esRAGE tagged with a stretch of 6, 10 and 14 of l-Asp were named D6-esRAGE, D10-esRAGE and D14-esRAGE, respectively.
For preparation of the first-strand cDNA, reverse transcriptase reaction was performed by using human lung total RNA. To amplify human esRAGE, D6-esRAGE, D10-esRAGE and D14-esRAGE, polymerase chain reactions were carried out with the following primers: esRAGE forward 5′-ctcgagCCAGGACCCTGGAA GGAAGCAGGA-3′ and reverse 5′-tctagaTTACATGTGTTGGGGGCTA TCTTC-3′: D6-esRAGE, forward 5′-ctcgagCCAGGACCCTGGAAGGAAG CAGGA-3′ and reverse 5′-tctagattaatcatc gtcgtcatcgtcggcctctgcttcaccggtCATGT GTTGGGGGCTATCTTC-3′: D10-esRAGE, forward 5′-ctcgagCCAGGACCCTGGAA GGAAGCAGGA-3′ and reverse 5′-tctag attagtcgtcgtcgtcatcatcgtcgtcatcgtcggcctc tgcttcaccggtCATGTGTTGGGGGCTATC TTC-3′: D14-esRAGE, forward 5′-ctcgagCCAG GACCCTGGAAGGAAG CAGGA-3′ and reverse 5′-tctagattaatcatc atcatcgtcgtcgtcgtcatcatcgtcgtcatcgtcggcc tctgcttcaccggtCATGTGTTGGGGGCTA TCTTC-3′. The nucleotide sequences compatible with 6, 10 or 14 l-Asp were added to the reverse primers used here. The amplified cDNAs were cloned and sequenced. The cDNAs were then transferred into XhoI-XbaI cloning sites of mammalian expression vector pcDNA3.1 (+).
The esRAGE, D6-esRAGE, D10-esRAGE and D14-esRAGE cDNAs subcloned in pcDNA3.1 (+) were then transfected into Chinese hamster ovary (CHO-K1) cells with Lipofectamine 2000 according to the manufacturer’s instruction. Selection of colonies was carried out in growth medium with DMEM supplemented with 10% heat-inactivated fetal bovine serum (FBS), plus 400 µg/mL G418 for 10–12 d. Individual clones were picked, grown to confluency and analyzed for protein expression by Western blot analysis in the medium as described below. The highest-producing clone was grown in collection medium with EX-CELL® 325 PF CHO Serum-Free Medium for CHO Cells (protein free) and 10% heat-inactivated FBS. When the cells reached confluency, the cells were rinsed with PBS and fed with collection medium without FBS to collect protein for further experiments.
Purification of Recombinant Proteins
Step 1. The medium containing each of the untagged and acidic oligopeptidetagged esRAGE protein was filtered through a 0.2-µm filter and then dialyzed against 25 mmol/L Tris buffer (pH 7.5) by using a Vivacell 70 centrifugal filter device.
Step 2. The dialyzed medium was applied to a column of DEAE-Sepharose equilibrated with 25 mmol/L Tris buffer (pH7.5). The column was first washed with 25 mmol/L Tris buffer (pH 7.5), and then the protein was eluted with 0–0.8 mol/L NaCl in a linear gradient.
Step 3. The eluted fractions containing the desired protein were pooled and dialyzed against 25 mmol/L Tris buffer (pH 7.5) by using a Vivaspin 15 centrifugal filter device.
Step 4. The dialyzed fractions were applied to a column of Heparin Sepharose equilibrated with 25 mmol/L Tris buffer (pH 7.5). The column was washed with 25 mmol/L Tris buffer (pH 7.5), and then the protein was eluted with 0–1.0 mol/L NaCl in a linear gradient.
Step 5. The eluted fractions containing the desired protein were pooled and dialyzed against phosphate-buffered saline (PBS) (pH 7.4) by using a Vivaspin 15 centrifugal filter device. The dialyzed fractions were then concentrated for step 6.
Step 6. The concentrated fractions were applied to a column of Sephacryl S-300-HR equilibrated with PBS. The protein was eluted with PBS.
Step 7. The eluted fractions containing the desired protein were pooled and concentrated after removal of endotoxin by using Detoxi-gel endotoxin removal gel. The concentrated fractions were stored at −80°C until use.
Western Blot Analysis
An analyte was subjected to SDS-PAGE and transferred to a polyvinylidene difluoride membrane. The membrane was probed with primary anti-RAGE antibody, followed by incubation with horseradish peroxidase-conjugated anti-rabbit IgG as a secondary antibody. Blots were developed with an ECL Plus kit and scanned using Typhoon 9410 (GE Healthcare).
HA beads were suspended in 50 mmol/L Tris-buffered saline, pH 7.4, at a concentration of 100 µg/100 µL. The purified esRAGE, D6-esRAGE, D10-esRAGE and D14-esRAGE were mixed with the HA suspension at final concentrations of 10, 20 and 40 µ/mL. The mixtures were agitated at 37°C for 1 h, followed by centrifugation at 12,000g for 5 min to capture the esRAGE-bound HA beads. The supernatants were analyzed by Western blot analysis to determine the amount of unbound esRAGE. The intensity of immunoreactive blots was quantified by using ImageQuant TL software (GE Healthcare). The concentration of untagged or acidic oligopeptide-tagged esRAGE in the supernatant was estimated from the separately established calibration curve containing the corresponding untagged and tagged esRAGEs in the range from 1.25 to 10 µg/mL. The amount of esRAGE bound to the HA beads was calculated by subtracting the amount of unbound protein from the total amount of esRAGE added to each tube. The dissociation constant (Kd) was determined from double-reciprocal plots.
Tissue Distribution of Untagged and Acidic Oligopeptide-Tagged esRAGE
A total of 1 mg/mL esRAGE, D6-esRAGE, D10-esRAGE and D14-esRAGE were respectively labeled with Alexa Fluor 488 Protein Labeling Kit following the manufacturer’s instructions. The Alexa-labeled esRAGE was injected into DBA/1J mice via the tail vein at a dose of 1 mg/kg body weight. Mice were killed at 6, 24, 72, 168 and 336 h after a single infusion, and legs, liver and kidney were dissected. The tissues were immersion-fixed in 10% neutral buffered formalin, embedded in paraffin and sectioned. Fluorescence images were taken with a confocal laser scanning microscope (LSM 510; Carl Zeiss, Jena, Germany).
Assay for HMGB1 Binding to esRAGE and D6-esRAGE
According to the results of tissue distribution study, significant difference among acidic oligopeptide-tagged esRAGEs was not observed. Therefore, HMGB1 binding assay was performed for esRAGE and D6-esRAGE. Nickel affinity gel was suspended in PBS containing 4 mmol/L imidazole at a final concentration of 10 v/v%. A total of 5 µg His-tagged HMGB1 was added into the nickel affinity gel suspension. The purified esRAGE and D6-esRAGE were respectively mixed with the suspension and agitated at 37°C for 30 min, in which gel complexes composed of nickel affinity gel, His-tagged HMGB1 and esRAGE or D6-esRAGE were allowed to form. The mixtures were centrifuged at 6,000g for 1 min to capture the gel complexes, and the gel complexes were washed three times with PBS containing 4 mmol/L imidazole. The gel complexes were agitated in PBS containing 250 mmol/L imidazole for 5 min to elute the esRAGE and D6-esRAGE from the gel complexes. After centrifugation at 6,000g for 1 min, the supernatants were analyzed by Western blot analysis to determine esRAGE and D6-esRAGE bound to His-tagged HMGB1.
Mouse Monocyte/Macrophage Cell Culture
According to the results of the tissue distribution study, a significant difference between acidic oligopeptide-tagged esRAGEs was not observed. Therefore, esRAGE and D6-esRAGE were used to test the effect on TNF-α production into cell culture medium. RAW264.7 cells were suspended in DMEM supplemented with 10% heat-inactivated FBS and seeded at 2 × 104 cells/well in a 96-well plate. At 24 h after the seeding, the cells were treated with the indicated concentration of HMGB1 in the presence or absence of esRAGE and D6-esRAGE. The cell culture medium was collected with the indicated time intervals after the HMGB1 treatment, and level of TNF-α in the medium was determined by using the ELISA kit.
Murine Model of Bovine Collagen Type II-Induced Arthritis
Six-week-old DBA/1J mice were housed in a room maintained at 24.5 ± 0.5°C on a 12:12-h light-dark cycle. They were allowed to acclimate for 1 wk before the start of experiments and free access to food and water. On d 0, the mice weighing 20–30 g were treated at the base of the tail intradermally with 150 µg bovine collagen type II dissolved in 0.1 mol/L acetic acid and emulsified in CFA. On d 21, the mice were challenged by subcutaneous injection of 150 µg bovine collagen type II in IFA (32,33). At 14 d after primary immunization, the mice were treated with esRAGE (1.0 mg/kg per week) or D6-esRAGE (1.0 mg/kg per week) intraperitoneally. Vehicle treatment (control) consisted of 100 µL PBS. Treatment was continued weekly in a total of three weekly injections, and mice were killed on d 34 after primary immunization. Arthritis was evaluated semiquantitatively by clinical and histopathological scoring in a blinded manner.
Clinical severity of arthritis was characterized by palpation and observations of joint properties and inflammation of surrounding tissues in each limb. The arthritis was graded on a scale of 0–3, using the previously published scoring system (34): 0 = normal, 1 = slight swelling and/or erythema of the fingers, 2 = pronounced edematous swelling and 3 = joint rigidity with edematous swelling or joint ankylosis. Scores of 1 and 2 mainly reflect reversible edematous inflammation, but a score of 3 reflects irreversible components such as established joint ankylosis. All four limbs were investigated, providing a maximum score of 12 per mouse as a cumulative grade.
Histopathological severity of arthritis was characterized by synovial lesion, cartilage destruction and bone destruction on hematoxylin and eosin (H&E)-stained sections and Safranin O-stained sections of knee joints. Severity of arthritis was assessed in a blinded manner by two independent investigators on a scale of 0–3, by using the following scoring system (35): synovial lesions: 0 = no lesions, 1 = mild effect, 2 = moderate effect/proliferation, and 3 = severe lesions with destruction; cartilage destruction: 0 = none, 1 = mild destruction of superficial cartilage, 2 = moderate destruction, and 3 = severe destruction with loss or complete fragmentation of cartilage; bone destruction: 0 = none, 1 = mild destruction of subchondral bone, 2 = moderate destruction, and 3 = severe destruction with loss of large areas of bone.
Statistical analysis was performed using one-way analysis of variance followed by the Tukey-Kramer post hoc test. Differences were considered to be significant at P < 0.05.
Characterization of Untagged and Acidic Oligopeptide-Tagged esRAGEs
esRAGE has two potential N-glycosylation sites (20). We examined whether the two protein bands have this type of modification and are derived from variants of N-linked oligosaccharides by using PNGase F, which specifically cleaves off oligosaccharides attached to asparagine residues. When the purified untagged esRAGE was treated with PNGase F, two protein bands with molecular masses of approximately 49 and 52 kDa disappeared, and one new band appeared at approximately 46 kDa, indicating that the untagged esRAGE was modified with two major variants of N-linked oligosaccharides (Figure 1A). The tagged esRAGE showed the same trend as the untagged esRAGE.
Because the action of acidic oligopeptide as a bone-targeting carrier attributes to binding affinity to HA, we examined the binding affinity of the untagged and tagged esRAGEs to HA in vitro. The binding parameter, Kd, of tagged esRAGEs was approximately 20-fold lower than that of untagged RAGE (esRAGE, 47.8 µg/mL; D6-esRAGE, 2.6 µg/mL; D10-esRAGE, 3.0 µg/mL; D14-esRAGE, 1.6 µg/mL), meaning the affinity of tagged esRAGEs to HA was greater than that of untagged esRAGE. However, no significant difference was observed between the tagged esRAGEs forms (Figure 1B).
Biodistribution of Untagged and Acidic Oligopeptide-Tagged esRAGE
HMGBl-Binding Affinity of esRAGE and D6-esRAGE
Blockade of HMGBl-Induced TNF-α Secretion by esRAGE and D6-esRAGE
Therapeutic Effects on Murine Collagen-Induced Arthritis by esRAGE and D6-esRAGE
We have demonstrated here that the current approach using D6-esRAGE ameliorates the characteristic pathological features on murine CIA. In the pathological process of RA, HMGB1 appears to be a key signal transduction ligand of TLR-2, TLR-4 and RAGE and is implicated in amplification of proinflammatory responses. Accumulation of HMGB1 in synovial fluids and serum of subjects with RA has been correlated with disease severity (9). These findings suggested that neutralization of the interactions between HMGB1 and the cell surface receptors via a soluble decoy receptor, sRAGE, is a potential therapeutic agent for RA. Hofmann et al. (38) reported that sRAGE administration ameliorates the clinical and histopathological features in murine CIA. However, the dose of administered sRAGE was substantially higher (daily 100 µg/mouse equivalent to weekly 35 mg/kg) compared with other biologics, implying that biological activity of sRAGE is lower and/or that biodistribution of sRAGE is unfavorable for treatment for CIA. Indeed, we observed that a much lower dose of esRAGE (weekly 1 mg/kg) showed little effectiveness on CIA. To resolve this issue and to prove the therapeutic effect of sRAGE, we hypothesized that drug delivery system to bone could be a valuable additive approach. Thus, we attempted to deliver esRAGE to bone by using a bone-targeting system.
It is known that the ligand-binding V-domain of RAGE contains two potential N-glycosylation sites, and PNGase F treatment reduces its molecular mass, indicating that the RAGE is a glycoprotein. In this study, both untagged and acidic oligopeptide-tagged esRAGEs expressed by CHO-K1 cells were highly glycosylated and were modified with two major variants of N-linked oligosaccharides. Both variants of N-linked oligosaccharides on esRAGE and D6-esRAGE showed a similar binding affinity to HMGB1 ligand. This finding implies that both variants function as a decoy receptor for HMGB1; therefore, we used both variants for further experiments. Recent studies revealed that the S100 protein levels in the serum and synovial fluids correlate with the arthritis severity as well as HMGB1 (39,40). S100 proteins bind to RAGE and TLR-4 and activate their downstream signals, resulting in increased production of matrix-degrading enzymes, such as matrix metalloproteinases, which are involved in cartilage degradation and progression of RA (41). It is likely that highly glycosylated esRAGE and D6-esRAGE have binding affinity to S100 proteins, since RAGE enriched for N-linked oligosaccharides shows higher binding affinity to S100 proteins as well as HMGB1 (42,43). Consistently, the binding affinity of diverse ligands such as HMGB1 and S100 proteins to RAGE decreases when RAGE is deglycosylated, indicating that the N-linked oligosaccharides on RAGE mediate the interaction with its ligands (42, 43, 44). However, structural influence of N-linked oligosaccharides on RAGE for ligand binding is not completely understood. Further analyses are needed to confirm that esRAGE and D6-esRAGE bind to ligands other than HMGB1.
A question addressed was whether administered D6-esRAGE could be delivered to relevant tissues. Pathological lesions in CIA appear not only in bone but also in synovial tissue, which does not contain HA. Consistent with the previous studies (27,28), acidic oligopeptide-tagged esRAGEs, including D6-esRAGE, were localized to a mineralized region in bone, where they were retained for over 1 week. The principle of bone-targeting by using an acidic oligopeptide is based on the affinity between negatively charged acidic oligopeptide and positively charged calcium in HA. Retention of D6-esRAGE was not observed in synovial tissue. In addition, D6-esRAGE was not distributed to avascular regions, such as articular cartilage and growth plate. Despite these facts, why did D6-esRAGE significantly attenuate the synovial hyperplasia in murine CIA while esRAGE showed little improvement? One can speculate that the prolonged retention of D6-esRAGE in bone provides a great chance to infiltrate D6-esRAGE into synovial tissue or cartilage via synovial fluids. Further pharmacokinetic study in synovial fluids is needed to answer this question.
Cumulative evidence demonstrates that the blockade of TNF-α is effective for patients with RA (5,45,46). Blocking TNF-α has been considered as a therapeutic option for RA treatment. However, in this study, despite substantial reduction of TNF-α level after weekly administration of esRAGE, the esRAGE-treated mice did not show improvement on synovial hyperplasia and bone destruction. This finding indicates that the reduction of TNF-α is insufficient to remit the pathological lesions on murine CIA. Several reports support our finding by proving that severe arthritis appeared in a TNF knockout murine model of CIA (47) and that HMGB1-triggered joint inflammation was observed in TNF knockout mice (48). Thus, even in the absence of TNF, both the inflammatory and destructive components could be induced, resulting in CIA. On the other hand, knockout mice lacking either IL-1 (49) or IL-6 (50) were protected from CIA. Our findings, therefore, provide the additional insights into implication of HMGB1 on TNF-independent mechanisms for RA pathogenesis.
The authors declare that they have no competing interests as defined by Molecular Medicine, or other interests that might be perceived to influence the results and discussion reported in this paper.
This work was supported by a grant-in-aid (type B) for young scientists, number 20790150, from the Ministry of Education, Culture, Sports, Science and Technology of Japan. Editorial assistance was provided by Michelle Stofa at the Nemours/Alfred I. duPont Hospital for Children.
- 6.Cohen S, et al. (2002) Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 46:614–24.CrossRefPubMedGoogle Scholar
- 7.Maini RN, et al.; CHARISMA Study Group. (2006) Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54:2817–29.CrossRefPubMedGoogle Scholar
- 10.Huttunen HJ, Fages C, Kuja-Panula J, Ridley AJ, Rauvala H. (2002) Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res. 62:4805–11.Google Scholar
- 18.Malherbe P, et al. (1999) cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. Brain Res. Mol. Brain Res. 71:159–70.CrossRefPubMedGoogle Scholar
- 40.Chen YS, Yan W, Geczy CL, Brown MA, Thomas R. (2009) Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res. Ther. 11:R39.CrossRefPubMedPubMedCentralGoogle Scholar
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.
The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)